Adequate Catchment Area Representation in Cancer Clinical Trials at NCI Designated Cancer Centers: The University of California Irvine Experience
Cancer Medicine · 2025
DOI: 10.1002/cam4.71327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Frank Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of California, Irvine School of Medicine, Irvine, California, USA. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Neoplasms, Patient Selection, Cancer Care Facilities. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Ensuring that clinical trial enrollment reflects the demographics and disease burden of a cancer center's catchment area is essential for improving trial accrual and the generalizability of research findings. We hypothesized that aligning the clinical trial portfolio with the needs of the catchment area can enhance enrollment and access to novel therapeutics.
Methods
A retrospective cohort study was conducted at the University of California Irvine Chao Family Comprehensive Cancer Center (CFCCC), an National Cancer Institute‐designated cancer center serving Orange County (OC), California—the 6th largest populous county in the United States. Clinical trial enrollment data from 2015 to 2023 were analyzed using the CFCCC clinical research database. Patient demographics, tumor types, and trial enrollment patterns were compared with population‐level data from NIH SEER for both OC and the United States.
Results
Between 2015 and 2023, 2317 participants were enrolled in clinical trials. Demographics were: White (66.4%), Asian (20.1%), Black (2.4%), American Indian/Alaska Native (0.7%), mixed/unknown (9.3%). Ethnicity: Non‐Hispanic (77.8%) vs. Hispanic (20.5%). Sex: Female (47.6%) vs. Male (52.3%). Age: < 70 years (73.3%) vs. ≥ 70 years (26.7%). Residence in low‐income/Health Professional Shortage Areas (HPSA): 44.8%. Trial phases included Phase I/II (35.6%), Phase II (25.4%), Phase II/III (2.8%), Phase III (26.6%), and Phase IV (0.3%). Study sponsors included Industry (61.1%), Institutional (23.6%), National (14.8%), and Externally Peer Reviewed (0.3%). Enrollment patterns reflected and, in some areas, exceeded the regional representation, particularly for Asian and Hispanic populations. Cancer‐type‐specific analysis showed higher enrollment for lung and liver cancers among Asians, breast cancer among Hispanics, and prostate cancer among Black patients.
Conclusions
These findings suggest that the strategic alignment of the clinical trial portfolio with the cancer burden and demographics of the catchment area can enhance accrual. This catchment‐based approach offers a scalable model for improving clinical trial participation and ensuring the relevance of research to the communities served.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- University of California, Irvine School of Medicine, Irvine, California, USA.
- Department of Medicine, University of California San Francisco, San Francisco, California, USA.
- Department of Medicine, University of California San Diego, San Diego, California, USA.
- Division of Hematology-Oncology, Department of Medicine, Chao Family Comprehensive Cancer Center, UC Irvine Health, Orange, California, USA.
ORCID-Profile: Frank Lee, Aditya Mahadevan, Farshid Dayyani
Zitieren
APA
Lee, F., Mahadevan, A., Azizi, A., Valerin, J., Mar, N., Jeyakumar, D., & Dayyani, F. (2025). Adequate Catchment Area Representation in Cancer Clinical Trials at NCI Designated Cancer Centers: The University of California Irvine Experience. Cancer Medicine. https://doi.org/10.1002/cam4.71327
Vancouver
Lee F, Mahadevan A, Azizi A, Valerin J, Mar N, Jeyakumar D, et al. Adequate Catchment Area Representation in Cancer Clinical Trials at NCI Designated Cancer Centers: The University of California Irvine Experience. Cancer Medicine. 2025. doi:10.1002/cam4.71327
BibTeX
@article{Lee2025,
author = {Lee, Frank and Mahadevan, Aditya and Azizi, Armon and Valerin, Jennifer and Mar, Nataliya and Jeyakumar, Deepa and Dayyani, Farshid},
title = {Adequate Catchment Area Representation in Cancer Clinical Trials at NCI Designated Cancer Centers: The University of California Irvine Experience},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71327}
}
EUVIMED